CY1113059T1 - Οργανικες ενωσεις - Google Patents

Οργανικες ενωσεις

Info

Publication number
CY1113059T1
CY1113059T1 CY20121100747T CY121100747T CY1113059T1 CY 1113059 T1 CY1113059 T1 CY 1113059T1 CY 20121100747 T CY20121100747 T CY 20121100747T CY 121100747 T CY121100747 T CY 121100747T CY 1113059 T1 CY1113059 T1 CY 1113059T1
Authority
CY
Cyprus
Prior art keywords
organic compounds
benzoyl staurosporin
warm
staurosporin
benzoyl
Prior art date
Application number
CY20121100747T
Other languages
Greek (el)
English (en)
Inventor
Pascale Hoehn
Bernd Koch
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35501294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113059(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1113059T1 publication Critical patent/CY1113059T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY20121100747T 2004-11-05 2012-08-21 Οργανικες ενωσεις CY1113059T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62534304P 2004-11-05 2004-11-05
US64213105P 2005-01-07 2005-01-07
EP05803350A EP1812448B1 (en) 2004-11-05 2005-11-03 Organic compounds

Publications (1)

Publication Number Publication Date
CY1113059T1 true CY1113059T1 (el) 2016-04-13

Family

ID=35501294

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100747T CY1113059T1 (el) 2004-11-05 2012-08-21 Οργανικες ενωσεις

Country Status (31)

Country Link
US (2) US8198435B2 (enExample)
EP (3) EP1812448B1 (enExample)
JP (4) JP5057986B2 (enExample)
KR (3) KR101333851B1 (enExample)
CN (2) CN102993213A (enExample)
AR (1) AR052322A1 (enExample)
AU (2) AU2005300693B2 (enExample)
BR (1) BRPI0517689A (enExample)
CA (1) CA2584911C (enExample)
CY (1) CY1113059T1 (enExample)
DK (1) DK1812448T3 (enExample)
EC (1) ECSP12007431A (enExample)
ES (1) ES2388142T3 (enExample)
GT (1) GT200500311A (enExample)
HK (1) HK1211587A1 (enExample)
HR (1) HRP20120652T1 (enExample)
IL (3) IL182691A (enExample)
JO (1) JO2897B1 (enExample)
MA (1) MA29033B1 (enExample)
MX (2) MX346525B (enExample)
MY (2) MY147404A (enExample)
NO (2) NO338960B1 (enExample)
NZ (3) NZ599033A (enExample)
PE (3) PE20130377A1 (enExample)
PL (1) PL1812448T3 (enExample)
PT (1) PT1812448E (enExample)
RU (2) RU2394038C2 (enExample)
SI (1) SI1812448T1 (enExample)
TN (1) TNSN07165A1 (enExample)
TW (4) TWI530500B (enExample)
WO (1) WO2006048296A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
KR20160008267A (ko) 2014-07-14 2016-01-22 주식회사 윈스 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템
EP3592749A1 (en) * 2017-03-06 2020-01-15 Teva Pharmaceutical Works Ltd. Solid state forms of midostaurin
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza
US20220242880A1 (en) * 2019-06-24 2022-08-04 Dr. Reddy?s Laboratories Limited Process for preparation of midostaurin
IT201900014346A1 (it) * 2019-08-08 2021-02-08 Procos Spa Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo
IT202000004291A1 (it) 2020-03-02 2021-09-02 Indena Spa Processo per la purificazione di alcaloidi indolo carbazolici
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2023205504A1 (en) * 2022-04-22 2023-10-26 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS60185719A (ja) 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5073633A (en) * 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
US5096330A (en) * 1990-06-21 1992-03-17 M-B-W Inc. Pitch control mechanism for a surface finishing machine
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH05247955A (ja) 1992-03-06 1993-09-24 Taisei Corp 擁壁の施工方法
US5344926A (en) 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
RU2191175C2 (ru) * 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
BR9917475B1 (pt) * 1999-08-30 2013-07-23 processo para a manufatura de compostos, e, modificação do processo.
CA2439097C (en) 2001-03-26 2010-10-12 Novartis Ag Pharmaceutical compositions
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
WO2004094645A1 (en) * 2003-04-22 2004-11-04 Lonza Ag Process for the recovery of staurosporine from a fermentation broth

Also Published As

Publication number Publication date
RU2467012C2 (ru) 2012-11-20
TW201247680A (en) 2012-12-01
PL1812448T3 (pl) 2012-10-31
GT200500311A (es) 2006-05-22
JP2012149099A (ja) 2012-08-09
IL207702A0 (en) 2010-12-30
JP5701246B2 (ja) 2015-04-15
TNSN07165A1 (en) 2008-11-21
US8198435B2 (en) 2012-06-12
PE20130377A1 (es) 2013-04-03
IL182691A0 (en) 2007-09-20
PE20090433A1 (es) 2009-05-05
US20090137552A1 (en) 2009-05-28
JP2008518995A (ja) 2008-06-05
RU2009137788A (ru) 2011-04-20
TWI530501B (zh) 2016-04-21
MY147404A (en) 2012-11-30
TWI530500B (zh) 2016-04-21
RU2007120695A (ru) 2008-12-10
EP2955186A1 (en) 2015-12-16
WO2006048296A1 (en) 2006-05-11
NO340404B1 (no) 2017-04-18
MY154878A (en) 2015-08-14
MX346525B (es) 2017-03-23
PT1812448E (pt) 2012-08-24
EP2272850A3 (en) 2011-09-21
AU2009245817A1 (en) 2009-12-24
BRPI0517689A (pt) 2008-10-14
US8710216B2 (en) 2014-04-29
JP2015063569A (ja) 2015-04-09
EP1812448B1 (en) 2012-05-23
TWI433852B (zh) 2014-04-11
NO20072290L (no) 2007-05-30
HRP20120652T1 (hr) 2012-09-30
EP1812448A1 (en) 2007-08-01
NO20161152A1 (no) 2007-05-30
US20120322789A1 (en) 2012-12-20
IL217571A (en) 2017-07-31
AR052322A1 (es) 2007-03-14
PE20060947A1 (es) 2006-10-30
JP2017061578A (ja) 2017-03-30
KR20070083979A (ko) 2007-08-24
KR101289998B1 (ko) 2013-07-30
CN102993213A (zh) 2013-03-27
AU2005300693B2 (en) 2010-08-19
NO338960B1 (no) 2016-11-07
HK1211587A1 (en) 2016-05-27
SI1812448T1 (sl) 2012-09-28
TW200628474A (en) 2006-08-16
JO2897B1 (en) 2015-09-15
TW201446773A (zh) 2014-12-16
AU2005300693A1 (en) 2006-05-11
MA29033B1 (fr) 2007-11-01
EP2272850A2 (en) 2011-01-12
NZ599033A (en) 2012-09-28
DK1812448T3 (da) 2012-08-27
NZ588025A (en) 2012-04-27
KR101333851B1 (ko) 2013-11-27
IL182691A (en) 2013-02-28
ECSP12007431A (es) 2012-06-29
TW201247681A (en) 2012-12-01
TWI455941B (zh) 2014-10-11
KR20120101600A (ko) 2012-09-13
CN102627658A (zh) 2012-08-08
AU2009245817B2 (en) 2013-02-21
CA2584911A1 (en) 2006-05-11
KR101265850B1 (ko) 2013-05-20
EP2272850B1 (en) 2017-05-10
JP5057986B2 (ja) 2012-10-24
HK1108881A1 (en) 2008-05-23
CA2584911C (en) 2017-10-24
KR20120101601A (ko) 2012-09-13
RU2394038C2 (ru) 2010-07-10
NZ554653A (en) 2010-10-29
MX2007005429A (es) 2007-05-18
ES2388142T3 (es) 2012-10-09
IL207702A (en) 2016-09-29

Similar Documents

Publication Publication Date Title
CY1113059T1 (el) Οργανικες ενωσεις
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
CY1114735T1 (el) Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5
CY1112516T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης και οι χρησεις τους
CY1107084T1 (el) Παραγωγα πυρρολοπυριδαζινης
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
CY1118978T1 (el) Μεθοδοι και συνθεσεις για την αυξηση της αποτελεσματικοτητας των θεραπευτικων αντισωματων με τη χρηση ενωσεων που διεγειρουν τα κυτταρα νκ
CY1113494T1 (el) 8-ΕΤΕΡΟΑΡΥΛΟ-3-ΑΛΚΥΛΟ-1,3-ΔΙΥΔΡΟ-ΙΜΙΔΑΖΟ[4,5-c]ΚΙΝΟΛΙΝ-2-ΟΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ ΡΙ-3
CY1118349T1 (el) Παραγοντες συνδεσης me cd19 και χρησεις αυτων
CY1117217T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης
CY1114397T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
EP1876990A4 (en) DENTAL TREATMENT THROUGH ALIGNMENT ELEMENTS
CY1110127T1 (el) Υποκατεστημενες 1-προπιολυλο-πιπεραζινες με χημικη συγγενεια για τον υποδοχεα mglur5 για τη θεραπεια καταστασεων πονου
CY1114277T1 (el) ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ
UY28314A1 (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
CY1113190T1 (el) Μεθοδος αγωγης της αιμολυτικης νοσου
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
CY1113485T1 (el) Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων
CY1119317T1 (el) Συνθεση για τοπικη εφαρμογη, χρησεις αυτης, συσκευη εφαρμογης και kit μερων
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
CY1113911T1 (el) Παραγωγα sf5 ως αναστολεις par1, η παρασκευη τους και η χρηση τους ως φαρμακα
CY1112614T1 (el) Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης
CY1113228T1 (el) Τριαζολοπυριδαζινες ως αναστολεις ραr1, η παρασκευη και η χρηση τους ως φαρμακα